216 related articles for article (PubMed ID: 29728708)
1. Emricasan, a pan-caspase inhibitor, improves survival and portal hypertension in a murine model of common bile-duct ligation.
Eguchi A; Koyama Y; Wree A; Johnson CD; Nakamura R; Povero D; Kneiber D; Tameda M; Contreras P; Spada A; Feldstein AE
J Mol Med (Berl); 2018 Jun; 96(6):575-583. PubMed ID: 29728708
[TBL] [Abstract][Full Text] [Related]
2. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
Garcia-Tsao G; Bosch J; Kayali Z; Harrison SA; Abdelmalek MF; Lawitz E; Satapathy SK; Ghabril M; Shiffman ML; Younes ZH; Thuluvath PJ; Berzigotti A; Albillos A; Robinson JM; Hagerty DT; Chan JL; Sanyal AJ;
J Hepatol; 2020 May; 72(5):885-895. PubMed ID: 31870950
[TBL] [Abstract][Full Text] [Related]
3. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis.
Barreyro FJ; Holod S; Finocchietto PV; Camino AM; Aquino JB; Avagnina A; Carreras MC; Poderoso JJ; Gores GJ
Liver Int; 2015 Mar; 35(3):953-66. PubMed ID: 24750664
[TBL] [Abstract][Full Text] [Related]
4. Emricasan (IDN-6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension.
Garcia-Tsao G; Fuchs M; Shiffman M; Borg BB; Pyrsopoulos N; Shetty K; Gallegos-Orozco JF; Reddy KR; Feyssa E; Chan JL; Yamashita M; Robinson JM; Spada AP; Hagerty DT; Bosch J
Hepatology; 2019 Feb; 69(2):717-728. PubMed ID: 30063802
[TBL] [Abstract][Full Text] [Related]
5. Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
Brusilovskaya K; Königshofer P; Lampach D; Szodl A; Supper P; Bauer D; Beer A; Stift J; Timelthaler G; Oberhuber G; Podesser BK; Seif M; Zinober K; Rohr-Udilova N; Trauner M; Reiberger T; Schwabl P
United European Gastroenterol J; 2020 Dec; 8(10):1174-1185. PubMed ID: 32878579
[TBL] [Abstract][Full Text] [Related]
6. Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo.
Frenette CT; Morelli G; Shiffman ML; Frederick RT; Rubin RA; Fallon MB; Cheng JT; Cave M; Khaderi SA; Massoud O; Pyrsopoulos N; Park JS; Robinson JM; Yamashita M; Spada AP; Chan JL; Hagerty DT
Clin Gastroenterol Hepatol; 2019 Mar; 17(4):774-783.e4. PubMed ID: 29913280
[TBL] [Abstract][Full Text] [Related]
7. AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model.
Hu L; Su L; Dong Z; Wu Y; Lv Y; George J; Wang J
J Mol Med (Berl); 2019 Mar; 97(3):423-434. PubMed ID: 30721324
[TBL] [Abstract][Full Text] [Related]
8. Cediranib ameliorates portal hypertensive syndrome via inhibition of VEGFR-2 signaling in cirrhotic rats.
Fan Q; Wu G; Chen M; Luo G; Wu Z; Huo H; Li H; Zheng L; Luo M
Eur J Pharmacol; 2024 Feb; 964():176278. PubMed ID: 38158116
[TBL] [Abstract][Full Text] [Related]
9. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
Harrison SA; Goodman Z; Jabbar A; Vemulapalli R; Younes ZH; Freilich B; Sheikh MY; Schattenberg JM; Kayali Z; Zivony A; Sheikh A; Garcia-Samaniego J; Satapathy SK; Therapondos G; Mena E; Schuppan D; Robinson J; Chan JL; Hagerty DT; Sanyal AJ
J Hepatol; 2020 May; 72(5):816-827. PubMed ID: 31887369
[TBL] [Abstract][Full Text] [Related]
10. The impact of emricasan on chronic liver diseases: current data.
Lekakis V; Cholongitas E
Clin J Gastroenterol; 2022 Apr; 15(2):271-285. PubMed ID: 35000120
[TBL] [Abstract][Full Text] [Related]
11. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
Frenette C; Kayali Z; Mena E; Mantry PS; Lucas KJ; Neff G; Rodriguez M; Thuluvath PJ; Weinberg E; Bhandari BR; Robinson J; Wedick N; Chan JL; Hagerty DT; Kowdley KV;
J Hepatol; 2021 Feb; 74(2):274-282. PubMed ID: 33038432
[TBL] [Abstract][Full Text] [Related]
12. Emricasan Ameliorates Portal Hypertension and Liver Fibrosis in Cirrhotic Rats Through a Hepatocyte-Mediated Paracrine Mechanism.
Gracia-Sancho J; Manicardi N; Ortega-Ribera M; Maeso-Díaz R; Guixé-Muntet S; Fernández-Iglesias A; Hide D; García-Calderó H; Boyer-Díaz Z; Contreras PC; Spada A; Bosch J
Hepatol Commun; 2019 Jul; 3(7):987-1000. PubMed ID: 31304452
[TBL] [Abstract][Full Text] [Related]
13. Endothelial nitric oxide synthase is not essential for the development of fibrosis and portal hypertension in bile duct ligated mice.
Koshy A; De Gottardi A; Ledermann M; Saegesser H; Shaw SG; Zimmermann A; Reichen J
Liver Int; 2005 Oct; 25(5):1044-52. PubMed ID: 16162165
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Intrahepatic and Intrasplenic Administration of Mesenchymal Stem Cell to Liver Function and Degree of Liver Fibrosis in Common Bile Duct Ligation Model in Rabbit.
Gunardi H; Alatas FS; Antarianto RD; Rahayatri TH
J Pediatr Surg; 2024 Apr; 59(4):634-639. PubMed ID: 38160190
[TBL] [Abstract][Full Text] [Related]
15. Electroacupuncture attenuates vascular hyporeactivity in a rat model of portal hypertension induced by bile duct ligation.
Chen YS; Wen CK; Liu GH; Lee TY
Acupunct Med; 2022 Feb; 40(1):68-77. PubMed ID: 34553631
[TBL] [Abstract][Full Text] [Related]
16. Deleterious effect of oltipraz on extrahepatic cholestasis in bile duct-ligated mice.
Weerachayaphorn J; Luo Y; Mennone A; Soroka CJ; Harry K; Boyer JL
J Hepatol; 2014 Jan; 60(1):160-6. PubMed ID: 23978715
[TBL] [Abstract][Full Text] [Related]
17. Role of thromboxane A2 in early BDL-induced portal hypertension.
Yokoyama Y; Xu H; Kresge N; Keller S; Sarmadi AH; Baveja R; Clemens MG; Zhang JX
Am J Physiol Gastrointest Liver Physiol; 2003 Mar; 284(3):G453-60. PubMed ID: 12431905
[TBL] [Abstract][Full Text] [Related]
18. Splenectomy ameliorates portal pressure and anemia in animal models of cirrhotic and non-cirrhotic portal hypertension.
Schwabl P; Seeland BA; Riedl F; Schubert TL; Königshofer P; Brusilovskaya K; Petrenko O; Hofer B; Schiefer AI; Trauner M; Peck-Radosavljevic M; Reiberger T
Adv Med Sci; 2022 Mar; 67(1):154-162. PubMed ID: 35272246
[TBL] [Abstract][Full Text] [Related]
19. Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats.
Coll M; Rodriguez S; Raurell I; Ezkurdia N; Brull A; Augustin S; Guardia J; Esteban R; Martell M; Genescà J
Hepatology; 2012 Nov; 56(5):1849-60. PubMed ID: 22610782
[TBL] [Abstract][Full Text] [Related]
20. Inflammasome Is Activated in the Liver of Cholestatic Patients and Aggravates Hepatic Injury in Bile Duct-Ligated Mouse.
Cai SY; Ge M; Mennone A; Hoque R; Ouyang X; Boyer JL
Cell Mol Gastroenterol Hepatol; 2020; 9(4):679-688. PubMed ID: 31887435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
